800-872-2273

Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

Study Title Principal Investigator
Multicenter, Post-Market Study to Assess Outcomes of Patients Treated With the AFX System Compared to Other EVAR Devices for Endovascular Abdominal Aortic Aneurysm Repair: LEOPARD
This study is a prospective, randomized, multi-center study, intended to evaluate the outcomes of contemporary EVAR (Endovascular Aneurysm Repair) in a real world population. The study is designed to compare the anatomically stabilized AFX Endograft System to a reference group of proximally fixated EVAR devices. Patients will be randomized between the two groups. Randomization will be 1:1. Each investigator will select one comparator device of their choice before enrolling the first patient. The study will sequentially evaluate non-inferiority and superiority hypotheses. Up to 80 sites with experience in EVAR and up to 800 subjects will participate in this study.
Not yet recruiting | Aneurysm | Not Multisite
Avyava Sharma
GREAT Global Registry for Endovascular Aortic TreatmentOutcomes Evaluation
This is a retrospective and prospective observational cohort Registry designed to obtain data on the use of the GORE® EXCLUDER® AAA Endoprosthesis with C3 Delivery System. Patient and device performance outcomes will be collected during treatment and throughout all post-treatment visits, including follow-up extending up to 10 years.
Active, not recruiting | Aneurysm | Not Multisite
Fred Weaver
View Research Profile
Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis for the Treatmentof Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms.
The primary objective of this study was to estimate the safety of the 31 mm GORE EXCLUDER® AAA Endoprosthesis as compared to open surgical repair when used in the treatment of infrarenal abdominal aortic aneurysms. A secondary objective was to compare device performance of the original GORE EXCLUDER® AAA Endoprosthesis to the 31mm EXCLUDER when used in the treatment of infrarenal abdominal aortic aneurysms.
Completed | Aneurysm | Not Multisite
Fred Weaver
View Research Profile
COAST: COILING OF ANEURYSMS SMALLER THAN 5 MM WITH HYPERSOFT
Rationale and Intervention:This is a prospective, single-arm, multi-center post-marketing data collection study to determine the safety and effectiveness of HyperSoft and HydroFrame/HydroSoft coils in the treatment of small intracranial aneurysms. HyperSoft Helical, HyperSoft 3 D and HydroFram/HydroSoft are newly designed coils where the shape and softness of these coils are designed for small aneurysms. There are 2 phases in this study. In Phase 1, participants will be enrolled if they will be treated with HyperSoft 3D and HyperSoft helical coils. When the sponsor adds phase 2, patients will be enrolled into Phase 2 if their aneurysm will be framed with HydroFrame HydroSoft 3D and finished with HyperSoft 3D and /or Hyper Soft helical coils. Objectives:The primary objective of this study is to assess clinical and imaging outcomes in the endovascular treatment of small ( 4.9 mm) intracranial aneurysms utilizing the HyperSoft 3D and HyperSoft helical coils specifically designed for the treatment of small aneurysms.Study Population: 300 participants who have been diagnosed with small ( 4.9 mm) intracranial aneurysms and who were treated with the coils from 16 centers. Study Methodology:Endovascular coiling of the aneurysm is performed per each institutions standard procedure.Data from each participant will be collected up to 12 months post procedure. There are up to five data points which include baseline (pre- procedure), procedure/post procedure through discharge and follow-up at 6 or 12 months. Data from imaging (2-D DSA, diagnostic) of aneurysm, clinical assessment (mRS, Hunt & Hess,NIHSS), aneurysm occlusion grading (Raymond-Roy grading scale /RRGS), retreatment and adverse events/safety will be collected per protocol at various time points. Study Endpoints or Outcomes:Efficacy: Raymond-Roy grading scale (RRGS) of 2 or better occlusion on follow-up angiography performed >150 days post embolization, not requiring retreatment.Safety: Freedom from new post-procedural bleeding and ischemic stroke associated with a 4-point worsening neurologically within 48 hours of aneurysm treatment or any new aneurysmal bleeding secondary to treated aneurysm. Follow up:All Study subjects will undergo follow-up angiographic (DSA or MRA) evaluations at 6 months and/or 12 months following the procedure or if an unscheduled visit is required.Statistics and Plans for Analysis:Two-sided 95% confidence intervals will be calculated about the estimated post EVT occlusion rates using the exact binomial distribution. Secondary analyses will include any neurological and mortality, bleeding rate of target aneurysms at one year (includes rebleeding of target ruptured aneurysms), recurrence rate/recanalization (at time of >150 day angiographic follow up), and retreatment rate (at one year). All clinical outcome analyses will be performed on the per protocol and ITT populations.
Recruiting | Aneurysm | Not Multisite
William Mack
View Research Profile
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
Abdominal aortic aneurysms (AAAs) are a common and life-threatening condition. The rate of aneurysm growth and the risk of rupture are related to aneurysm size. Aortic diameter is the single best predictor of rupture risk. AAAs are typically asymptomatic and spontaneous rupture of an aneurysm is usually fatal. A number of antibiotics have been proposed as a treatment for AAA with varying rationales. One line of reasoning is that AAA progression is enhanced by secondary infection within the aortic wall. Chlamydia pneumonia has been found in atherosclerotic plaque and the wall of abdominal aortic aneurysms. The tetracycline antibiotics have been studied because of their known inhibition of matrix metalloproteinases (MMP). Although studies in mice and rats have shown that doxycycline can slow down the growth of aneurysms, there have only been a few small studies in humans that have not provided a definitive answer. The purpose of the study is to determine whether doxycycline administration can decrease the rate of growth of small abdominal aortic aneurysms. About 250 participants aged 55 and older with a small abdominal aortic aneurysm will be enrolled in this study; about 20 participants at USC. Participants will be randomized to doxycycline or placebo. Participants will be followed for two years with imaging studies and lab tests for various biomarkers as well as qualify of life questionnaires. in addition, they will be monitored for adverse events. The primary study endpoint is the transverse diameter of the aneurysm over the two year period. Secondary endpoints will include evaluation of biomarkers and quality of life. The sponsor will conduct the statistical analysis to assess the safety and efficacy of doxycycline, the change in size of aneurysm.
Active, not recruiting | Aneurysm | Multisite
Fred Weaver
View Research Profile
Powered by SC CTSI